Mesoblast
Mesoblast Ltd is an Australian clinical-stage biopharmaceutical company developing allogeneic cellular medicines for inflammatory and degenerative diseases. The company utilizes its proprietary mesenchymal lineage cell technology to advance cell therapy candidates including Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease (aGVHD) and rexlemestrocel-L for chronic heart failure. Main revenue drivers currently consist of milestone payments, research development grants, commercial licensing royalties, and product sales. Mesoblast targets pediatric oncologists, transplant specialists, cardiologists, clinical research centers, and patients across the United States, Europe, and Asia-Pacific. The company holds a market-leading global position in allogeneic mesenchymal cell therapy development. Headquartered in Melbourne, Victoria, Australia, Mesoblast Ltd is listed on the Australian Securities Exchange and the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Mesoblast.
- Legal name
- Mesoblast Ltd
- Sector
- Health Care
- Country
- Australia
- Funds holding it
- 4
Funds holding Mesoblast
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)